Apogee Therapeutics (NASDAQ:APGE) Receives "Outperform" Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research report sent to investors on Monday, RTT News reports. They currently have a $87.00 price target on the stock. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.60) EPS, […]